Freeze

This documentation pertains to May 2025 Freeze of the CSF Roche Elecsys NTK2 - Gothenburg dataset.


Origin

These cerebrospinal fluid assay results come from the laboratory of Henrik Zetterberg and Kaj Blennow.

Sample Selection

Samples were included from observations at which at least one aliquot of CSF was available that had been stored in a Sarstedt 0.5 mL screw top tube.

For detailed information, refer to the WRAP and/or ADRC pre-analytic protocols for CSF and plasma collection, available on the Wisconsin Alzheimer's Program KnowledgeBase.

Sample and Participant Characteristics

This dataset includes 522 observations on 426 participants (213 ADRC; 213 WRAP; 276 female; 39 URG; 27 MCI and 6 Dementia at first visit; 25 MCI and 8 Dementia at last visit; <5 participant(s) are aged 90+, of those not: mean first and last ages of 65.0 and 65.4, respectively; mean first and last days since baseline of 3089 and 3269, respectively). Per data sharing agreements with the Oneida nation, data from Native American participants are not included in this dataset.

Analytes

• Amyloid beta 40 [Gen2] (ABeta_1_42; pg/mL)
• Amyloid beta 42 [Gen2] (ABeta_1_40; pg/mL)
• Phosphorylated tau 181 (pTau; pg/mL)
• Total tau (tTau; pg/mL)
• Neurogranin (pg/mL)
• Neurofilament light-chain (NFL; pg/mL)
• Alpha synuclein (a_Synuclein; pg/mL)
• Glial fibrillary acidic protein (GFAP; ng/mL)
• sTREM2 (ng/mL)
• YKL40 (ng/mL)
• Neuronal pentraxin 2 (nptx2)
• Snap-25 (snap25)

Derived Variables

• AB42/AB40
• pTau181/AB42
• pTau181 binary
• AB42/AB40 binary
• pTau181/AB42 binary

Detection Limits

• AB42: 150-2500 pg/mL
• pTau181: 8-120 pg/mL
• tTau: LLOQ 80 pg/mL

Methods

The first paper describing the use of these markers in the Wisconsin cohorts is here:

Van Hulle C, Jonaitis EM, Betthauser TJ, et al. An examination of a novel multipanel of CSF biomarkers in the Alzheimers disease clinical and pathological continuum. Alzheimers Dement. 2021;17(3):431-445. https://doi.org/doi:10.1002/alz.12204

However, it should be noted that this paper used the Gen1 version of the amyloid assays. In mid 2022, a new version of the Ab42 assay was released that has superior detection limits. This Gen2 version of these assays is what has been applied in this dataset. Cutpoints for amyloid positivity in this new dataset were computed following the same methods as in Van Hulle et al (2021).

Data sheets

1. Electrochemiluminescence immunoassay (ECLIA) for the in vitro quantitative determination of phosphorylated Tau in human Cerebrospinal fluid (CSF). Published online 2017. URL: https://diagnostics.roche.com/us/en/products/params/elecsys-ptau.html
2. Electrochemiluminescence immunoassay (ECLIA) for the in vitro quantitative determination of ß-Amyloid (1-42) in human Cerebrospinal fluid (CSF). Published online 2017. URL: https://diagnostics.roche.com/us/en/products/params/elecsys-abeta42.html
3. Electrochemiluminescence immunoassay (ECLIA) for the in vitro quantitative determination of total Tau in human Cerebrospinal fluid (CSF). Published online 2017. URL: https://diagnostics.roche.com/us/en/products/params/elecsys-ttau.html

Data Dictionary

Funding / Acknowledgments

Papers including data obtained from these assays should acknowledge NIH R01 AG027161 (the Wisconsin Registry for Alzheimer's Prevention) and/or NIH P30 AG062715 (the Wisconsin Alzheimer's Disease Research Center).

Papers with Wisconsin coauthors that include data from this set must submit abstracts, posters, talks and papers to Roche for pre-publication review.